Discuss the strategic deployment of European litigation venues for US pharma companies, including the UK High Court litigation, UPC proceedings and EPO oppositions, and compare the impacts on injunction risk, cost exposure, and global settlement dynamics.
Examine how branded and biosimilar companies build, litigate, and defend formulation and delivery patents as core composition claims expire and these assets become the last line of exclusivity.
How the Canadian and American court system deals with medical treatment and dosage cases, including Janssen Inc. v. Pharmascience Inc. (Supreme Court of Canada).
How enforcement, settlement posture, and leverage change once the first generic or biosimilar has already entered the market.
A focused look at litigating patents in India where manufacturing scale, pricing pressure, and public-interest arguments materially affect outcomes.
Olivier Marchand is Regenerative Agriculture Manager at Nestlé, with over 20 years of experience driving sustainability, quality, and responsible practices across value chains.
With a strong background in purchasing, quality assurance, and agriculture, he has worked across Europe, Africa, Latin America, and Asia, bringing a global and cross-cultural perspective. He focuses on strengthening traceability, sustainability, and trust, helping meet growing consumer expectations around product origin, production methods, and social responsibility.
Sébastien Roumegous is a soil specialist and impact entrepreneur focused on scaling regenerative agriculture. As CEO of BIOSPHERES, Europe’s leading regenerative agriculture company, he supports businesses and public actors in transitioning toward high-performing, ecosystem-restoring farming systems.
With over 15 years of experience across 22 countries and 200,000 hectares in transition, his work combines technical expertise with a pragmatic, field-driven approach to improve soil health, biodiversity, and farmers’ livelihoods. Raised in a farming environment in southern France, he brings a grounded, results-oriented perspective to large-scale agricultural transformation. He recently published his first book on regenerative agriculture.
How MedTech companies assess exposure to standard essential patents as connectivity standards become embedded in devices, including licensing strategy and litigation risk.
How and why US-based companies are using Brazilian litigation as part of their cross-border enforcement and settlement strategies, including the ease of injunctions, speed and increasing success in tech-based cases.
How companies design settlements that address multiple products and patents while managing future releases, portfolio scope, and downstream risk.